- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03088865
Evaluation of an Internal Hospital Practice: The Effect of Altered Test Tubes Sampling Order on Blood Culture Contamination Rates
July 28, 2020 updated by: Hadassah Medical Organization
Evaluation of an Internal Hospital Practice: The Effect of Altered Sampling Protocol on Blood Culture Contamination Rates: An Open, Randomized, Prospective Study
Implementation of the initial specimen diversion technique, in which the first milliliter of the venipuncture sample is not injected into the culture bottle, led to a significant reduction in blood culture contamination rates.
This technique is based on the assumption that the skin plug aspirated during venipuncture is a major source of contaminating bacteria.
One such diversion method is aspirating the first blood volume into a blood collection tube.
It has, however, been suggested that regular blood collection tubes carry contaminants from the tube's stopper into the blood cultures drawn afterwards, thereby increasing contamination rates.
The aim of this trial is to examine the effect of aspirating the first blood volume into a regular blood collection tube on blood culture contamination rate.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
756
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Hadassah Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults evaluated in the emergency room or as inpatients for suspected sepsis or having sepsis and from whom the treating physician plans to take, in the same venous puncture, blood cultures and additional blood tests (blood count and/or blood chemistry).
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Initial Specimen Diversion
Aspirating first blood volume into a regular blood collection tube
|
order of blood drawing
|
|
Active Comparator: Standard practice
Aspirating first blood into blood culture bottles (Standard practice)
|
order of blood drawing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood culture contamination rate
Time Frame: 7 days
|
A blood culture contamination is defined as growth in a single set of coagulase-negative Staphylococcus, Micrococcus, Viridans group Streptococcus, Propionibacterium acne, Corynebacterium sp (diphtheroids) or Bacillus sp.
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2017
Primary Completion (Actual)
September 6, 2018
Study Completion (Actual)
September 6, 2018
Study Registration Dates
First Submitted
March 9, 2017
First Submitted That Met QC Criteria
March 19, 2017
First Posted (Actual)
March 23, 2017
Study Record Updates
Last Update Posted (Actual)
July 29, 2020
Last Update Submitted That Met QC Criteria
July 28, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0017-17-HMO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septicemia
-
University Hospital, BordeauxAquitaine MicrobiologieCompletedSepticemia in HemodialysisFrance
-
National Taiwan University HospitalCompletedMethicillin-resistant Staphylococcus Aureus SepticemiaTaiwan
-
Miquel PujolInstitut d'Investigació Biomèdica de Bellvitge; Instituto de Salud Carlos IIITerminatedMethicillin Susceptible Staphylococcus Aureus SepticemiaSpain
-
Centre Hospitalier Universitaire DijonCompleted
-
Minia UniversityNot yet recruiting
-
McGill University Health Centre/Research Institute...CompletedBacteremia | Methicillin Susceptible Staphylococcus Aureus SepticemiaCanada
-
Makerere UniversityCentre For International HealthCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
Chiang Mai UniversityUnknown
-
Magnolia Medical Technologies, Inc.CompletedSepticemiaUnited States
Clinical Trials on aspirating first blood volume into a regular blood collection tube
-
Centre Hospitalier Universitaire DijonCompleted
-
Institut CurieCompletedVolunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 InfectionFrance
-
Joslin Diabetes CenterActive, not recruiting
-
Centre Hospitalier de CayenneEuropean Regional Development FundRecruitingChildren | Dengue Fever | AdultsFrance
-
San Rocco TherapeuticsActive, not recruitingConfirmed Diagnosis of ß-thalassemia MajorItaly
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma... and other conditionsUnited States